Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.46 |
| ▸ | ABHD6 | Q9BV23 | 8/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.43 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 3/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.38 |
| ▸ | ACACB | O00763 | 2/20 | 0.36 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.36 |
| ▸ | KRAS | P01116 | 1/20 | 0.36 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25297104 | 1.00 | LOXL2 (0.46) | LOXL2ABHD6P2RX3P2RX2CYP11B2 | |
| SCHEMBL30261951 | 0.85 | GPR119 (0.41) | GPR119 | |
| SCHEMBL26095331 | 0.85 | GPR119 (0.41) | GPR119 | |
| SCHEMBL25301218 | 0.85 | LOXL2 (0.47) | LOXL2ABHD6MGLL | |
| SCHEMBL31080119 | 0.85 | ABHD6 (0.41) | ABHD6P2RX3P2RX2CYP11B2GPR119 | |
| SCHEMBL30395790 | 0.82 | GPR119 (0.45) | LOXL2ABHD6P2RX3P2RX2MGLL | |
| SCHEMBL25255551 | 0.82 | GPR119 (0.45) | LOXL2ABHD6P2RX3P2RX2MGLL | |
| SCHEMBL23850304 | 0.79 | HSD11B1 (0.47) | ABHD6P2RX3P2RX2MGLLGPR119 | |
| SCHEMBL30490333 | 0.79 | P2RX3 (0.45) | LOXL2ABHD6P2RX3P2RX2MGLL | |
| SCHEMBL25328658 | 0.79 | P2RX3 (0.46) | ABHD6P2RX3P2RX2MGLLGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119301113-A | Novel heterocyclic carbonyl cyclic compounds as MAGL inhibitors | 豪夫迈·罗氏有限公司 | 2025-01-10 | — | — | CN | disclosed |
| WO-2023247670-A1 | NEW HETEROCYCLIC-CARBONYL-CYCLIC COMPOUNDS AS MAGL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-12-28 | — | — | WO | disclosed |
| EP-4208456-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-07-12 | — | — | EP | disclosed |
| CN-115989228-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2023-04-18 | — | — | CN | disclosed |
| US-20220098176-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098176-A1 | HETEROCYCLIC COMPOUNDS | CBR3, BRIX1, CCNY | LOXL2 232/4885ABHD6 2620/4885P2RX3 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.